OKYO Pharma (OKYO) Receivables - Other (2021 - 2026)

OKYO Pharma (OKYO) has reported Receivables - Other for 6 consecutive years, with $4500.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables - Other changed 0.0% year-over-year to $4500.0 in Q1 2026; TTM through Mar 2026 was $4500.0, a 0.0% change from a year earlier, with the FY2026 full-year figure at $375749.0, up 55.05% from the prior year.
• Receivables - Other was $4500.0 for Q1 2026 at OKYO Pharma, down from $422281.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $422281.0 in Q3 2025 and troughed at $4500.0 in Q1 2025.
• A 5-year average of $182648.1 and a median of $163571.0 in 2022 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other tumbled 100.0% in 2022 and surged 1145.06% in 2023, its largest moves.
• Over 5 years, Receivables - Other stood at $27376.0 in 2022, then jumped by 995.0% to $299766.0 in 2023, then climbed by 18.87% to $356329.0 in 2024, then grew by 18.51% to $422281.0 in 2025, then plunged by 98.93% to $4500.0 in 2026.
• The last three Receivables - Other figures came in at $4500.0 (Q1 2026), $422281.0 (Q3 2025), and $4500.0 (Q1 2025), per Business Quant data.